In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 1.16 above Mink Therapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry 115 other companies have achieved higher Quick Ratio than Mink Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1328 to 2054.

Explain Quick Ratio?
How much Cash & cash equivalents INKT�s has?
What are INKT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

INKT Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	-1.16 %	-32.63 %	-28.09 %	4.18 %	-24.54 %
Y / Y Cash & cash equivalent Change	423.63 %	194.47 %	191.9 %	50.12 %	-81.94 %
Quick Ratio MRQ	1.16	2.02	2.67	1.23	0.22
INKT's Total Ranking	# 2054	# 1328	# 864	# 2494	#
Seq. Current Liabilities Change	60.43 %	-5.73 %	-35.08 %	0.67 %	9.35 %
Seq. Cash & cash equivalent Change	-7.55 %	-28.7 %	40.63 %	464.83 %	-48.01 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 116
Healthcare Sector	# 650
Overall Market	# 2054

Quick Ratio Statistics
High	Average	Low
2.67	1.1	0.01
(Dec 31 2025)		(Sep 30 2021)

Financial Statements
Mink Therapeutics Inc 's Current Liabilities	$ 8 Millions	Visit INKT's Balance sheet
Mink Therapeutics Inc 's Cash & cash equivalent	$ 9 Millions	Visit INKT's Balance sheet
Source of INKT's Sales		Visit INKT's Sales by Geography

Cumulative Mink Therapeutics Inc 's Quick Ratio

INKT's Quick Ratio for the trailling 12 Months

INKT Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-13.85 %	-20.38 %	-23.14 %	-26.79 %	-32.6 %
Y / Y Cash & cash equivalent TTM Growth	160.35 %	45.26 %	6.69 %	-23.49 %	-36.45 %
Quick Ratio TTM	1.65	1.36	1.01	0.65	0.55
Total Ranking TTM	# 3511	# 4019	# 3136	# 2937	#
Seq. Current Liabilities TTM Growth	-0.35 %	-8.35 %	-6.67 %	1.07 %	-7.9 %
Seq. Cash & cash equivalent TTM Growth	20.91 %	22.65 %	46.24 %	20.05 %	-32.54 %

Quick ratio ranking by company, industry and sector >> Back to INKT Financial Strength Comparisons >> Go to Compare INKT Quick Ratio to its Competitors

News about Mink Therapeutics Inc Quick Ratio

MiNK Therapeutics Raises $5.8 Million in Private Placement and Bolsters Clinical Trials with Board Observer Appointment

MiNK Therapeutics Secures $5.8 Million in Private Placement and Adds Board Observer for Accelerated Clinical Trials of MiNK-215
NEW YORK, May 13, 2024 - MiNK Therapeutics, Inc. (NASDAQ: INKT), a trailblazing clinical-stage biopharmaceutical company focused on the development, discovery, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies, has recently announced a significant milestone in its journey. The company disclosed that it has entered into a stock purchase agreement, raising $5.8 million through a private placement financing (PIPE). The newly infused capital will be directed towards expediting the clinical trials of MiNK-215, their leading allogeneic CAR-iNKT cell therapy aimed at targeting fibroblast activation protein (FAP) in solid tumors. MiNK Therapeutics plans to initiate clinical testing for MiNK-215 in early 2025.
The successful completion of this private placement financing signifies a new chapter of progress for MiNK Therapeutics. By securing $5.8 million in additional funds, the company is empowered to accelerate the advancement of MiNK-215, a promising iNKT cell therapy that has demonstrated remarkable potential in combating solid tumors. With solid tumors accounting for a significant portion of cancer cases worldwide, the urgent need for effective treatment options has been a driving force behind MiNK Therapeutics ongoing research and development efforts.

On the trailing twelve months basis INKT Cash & cash equivalent more than doubled by 423.63 % in Q2 2026 year on year, while Current Liabilities soared to $8 millions, this led to increase in in Mink Therapeutics Inc 's Quick Ratio to 1.65, above INKT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 145 other companies have achieved higher Quick Ratio than Mink Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 3511, from total ranking during the twelve months ending first quarter 2026 at 4019.

Explain Quick Ratio?
How much Cash & cash equivalents INKT�s has?
What are INKT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 146
Healthcare Sector	# 914
Within the Market	# 3511

trailing twelve months Quick Ratio Statistics
High	Average	Low
1.79	0.87	0.4
(Sep 30 2022)		(Jun 30 2025)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Sutro Biopharma Inc	3.11	$ 164.346 Millions	$ 52.898 Millions
Editas Medicine Inc	3.09	$ 211.645 Millions	$ 68.434 Millions
Autolus Therapeutics Plc	2.93	$ 201.630 Millions	$ 68.790 Millions
Moderna Inc	2.73	$ 6,910.000 Millions	$ 2,534.000 Millions
Sana Biotechnology Inc	2.59	$ 320.990 Millions	$ 123.752 Millions
Tarsus Pharmaceuticals Inc	2.56	$ 449.690 Millions	$ 175.753 Millions
Meiragtx Holdings Plc	2.46	$ 143.166 Millions	$ 58.096 Millions
Kodiak Sciences Inc	2.39	$ 125.903 Millions	$ 52.770 Millions
Exelixis Inc	2.32	$ 839.385 Millions	$ 361.927 Millions
Precision Biosciences Inc	2.19	$ 87.549 Millions	$ 39.886 Millions
Novavax inc	2.18	$ 719.340 Millions	$ 330.574 Millions
Regenxbio Inc	2.11	$ 174.530 Millions	$ 82.621 Millions
Biocardia Inc	2.00	$ 4.117 Millions	$ 2.055 Millions
Kymera Therapeutics Inc	1.75	$ 124.477 Millions	$ 71.326 Millions
Biocryst Pharmaceuticals Inc	1.69	$ 353.279 Millions	$ 208.846 Millions
Coherus Oncology inc	1.69	$ 127.683 Millions	$ 75.510 Millions
Bio techne Corp	1.62	$ 264.712 Millions	$ 163.700 Millions
Atara Biotherapeutics Inc	1.45	$ 9.900 Millions	$ 6.847 Millions
Twist Bioscience Corporation	1.39	$ 166.839 Millions	$ 120.255 Millions
Neumora Therapeutics Inc	1.34	$ 116.834 Millions	$ 87.478 Millions
Calidi Biotherapeutics Inc	1.33	$ 4.290 Millions	$ 3.237 Millions
Passage Bio Inc	1.17	$ 24.155 Millions	$ 20.719 Millions
Mink Therapeutics Inc	1.16	$ 8.807 Millions	$ 7.569 Millions
Amgen Inc	1.07	$ 27,404.000 Millions	$ 25,502.000 Millions
Aligos Therapeutics Inc	1.07	$ 30.381 Millions	$ 28.343 Millions
Vaxart Inc	1.05	$ 77.058 Millions	$ 73.108 Millions
Iovance Biotherapeutics inc	1.04	$ 110.768 Millions	$ 106.848 Millions
Liminatus Pharma Inc	0.99	$ 3.017 Millions	$ 3.040 Millions
Elutia Inc	0.95	$ 19.896 Millions	$ 21.045 Millions
Jasper Therapeutics Inc	0.93	$ 7.314 Millions	$ 7.845 Millions

Date modified: 2026-09-12T06:26:07+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.